We are live on ! Find out more
AG

Artal Group Portfolio holdings

AUM $1.01B
1-Year Est. Return 29.84%
This Fund
S&P 500
This Quarter Est. Return
-4.94%
1 Year Est. Return
+29.84%
3 Year Est. Return
+144%
5 Year Est. Return
+76.57%
10 Year Est. Return
+1,417.6%
AUM
$3.07B
AUM Growth
-$107M
Cap. Flow
+$22.9M
Cap. Flow %
0.75%
Top 10 Hldgs %
75.54%
Holding
110
New
22
Increased
17
Reduced
17
Closed
30

Sector Composition

Rank Sector Weight
1 Consumer Discretionary 35.8%
2 Healthcare 25.27%
3 Industrials 0.67%
4 Financials 0.63%
5 Real Estate 0.28%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
META icon
101
Meta Platforms (Facebook)
META
$1.5T
-250,000
Closed -$6.22M
SLB icon
102
SLB Ltd
SLB
$74.1B
-75,000
Closed -$5.38M
VLO icon
103
CALL
Valero Energy
VLO
$90B
-200,000
Closed -$6.95M
ONIT
104
Onity Group
ONIT
$339M
-23,333
Closed -$17.6M
ROC
105
CALL
DELISTED
ROCKWOOD HLDGS INC
ROC
-100,000
Closed -$6.4M
FRX
106
CALL
DELISTED
FOREST LABORATORIES INC
FRX
-300,000
Closed -$12.3M
ONXX
107
CALL
DELISTED
ONYX PHARMACEUTICALS INC
ONXX
-300,000
Closed -$26M
ONXX
108
DELISTED
ONYX PHARMACEUTICALS INC
ONXX
-300,000
Closed -$26M
MVISW
109
DELISTED
MICROVISION INC WTS
MVISW
-360,515
Closed -$11K
VVUS
110
CALL
DELISTED
Vivus Inc
VVUS
-20,000
Closed -$2.52M

Similar funds

Artal Group's Q3 2013 Portfolio in Review

As of Q3 2013, Artal Group held 110 positions worth $3.07B, down 3.4% from $3.18B the previous quarter. Its ten largest holdings account for 76% of the portfolio.

Artal Group's Q3 2013 filing shows 22 new, 17 increased, 17 reduced and 30 closed positions. Its largest new stake was Anywhere Real Estate: 200,000 shares worth $8.6M. The largest sale was ONYX PHARMACEUTICALS INC, an estimated $26M.

By sector, the portfolio is most concentrated in Consumer Discretionary at 36% of assets, down from 42% a quarter earlier, followed by Healthcare and Industrials.

  • Artal Group's largest Q3 2013 buy was Anywhere Real Estate: 200,000 shares worth $8.6M.
  • Artal Group added most to Ford in Q3 2013, an estimated $5.07M increase.
  • Artal Group's biggest Q3 2013 reduction was Acorda Therapeutics, cutting an estimated $14.5M.
  • Artal Group fully exited ONYX PHARMACEUTICALS INC in Q3 2013, selling an estimated $26M.
  • Artal Group's ten largest holdings make up 76% of its $3.07B portfolio in Q3 2013.
  • Artal Group opened 22 new positions and closed 30 in Q3 2013.
  • Artal Group's portfolio value fell 3.4% quarter-over-quarter to $3.07B.

Based on Artal Group's 13F filing for Q3 2013, filed 14 Nov 2013.